I’ve been in the business of helping couples build families for decades now, and there’s a deep satisfaction in seeing dreams come to life. Yet, as I sit in my clinic, surrounded by the hum of machinery and the soft glow of monitors, I’m reminded of the complexities of this field, especially as technology advances at breakneck speed. One of the latest buzzwords in our industry is artificial intelligence, particularly its application in embryo grading. I’ve had several embryologists walk into my office, excited about the possibilities AI might bring to our practice. But if I’m being candid, I don’t trust AI to grade embryos—not yet, at least.
Let me take you back to a conversation I had with a young embryologist, fresh out of training. She was brimming with enthusiasm about an AI tool that promised to revolutionize embryo selection. “Dr. Malpani,” she said, “this AI can predict pregnancy success better than we can!” Her excitement was infectious, but I couldn’t help but recall the countless times I’ve had to break the news of a failed cycle to hopeful parents, despite having transferred what we believed was the ‘perfect’ embryo.
In my experience, the allure of AI in embryo grading is akin to the allure of any new technology—it’s shiny, promising, and comes with the hope of eliminating human error. But the practice of medicine, much like angel investing, has taught me to be wary of promises that seem too good to be true. In my IVF practice, I don’t promise miracles because I know the unpredictability of human biology.
AI, no matter how advanced, is still dependent on the data it’s fed. In a recent study, AI-guided assessments increased the agreement between embryologists, but the accuracy still hovered around 50-66%—a modest improvement, but far from the panacea it’s touted to be. The tool, however, is only as good as the images and scenarios it has been trained on. It’s crucial to remember that AI lacks the nuanced understanding of context that comes with years of human experience.
Consider the startup world, where I often see founders presenting polished decks and promising groundbreaking products. As an angel investor, I’ve learned to look beyond the surface. I ask the tough questions: What happens when the market shifts? How does your product adapt? Similarly, I question how AI handles the myriad of variables in embryo development. What happens when an embryo looks perfect on the outside but has underlying issues that an AI can’t detect?
The variability in embryologists’ assessments—often seen as a flaw that AI can correct—actually highlights the need for a more nuanced approach. Each embryo is unique, much like each startup, and requires a personalized touch. In the Indian healthcare system, where variables like patient demographics and resource availability vary widely, relying solely on AI could lead to oversights. We need to consider the transparency patients deserve and ensure that technology complements human expertise, not replaces it.
Moreover, the trust placed in AI by less experienced embryologists raises a red flag. In my practice, I’ve seen younger doctors lean heavily on technology, sometimes at the expense of honing their observational skills. It’s akin to a founder who relies solely on data analytics without understanding market sentiment. AI is a tool, not a crutch. We must teach our young professionals the art of balancing technology with instinct—a lesson I’ve learned both in the clinic and the boardroom.
The argument isn’t against AI itself but rather its current application and the blind faith we sometimes place in it. AI has potential, yes, but it needs rigorous testing, adaptation, and most importantly, it needs to earn our trust. I believe in a future where AI and embryologists work hand-in-hand, each enhancing the other’s strengths. But until then, I remain cautious.
In the end, it’s the human touch that makes the difference. It’s the ability to see beyond the data, to understand the emotional and physiological complexities of each patient. Much like in investing, where understanding a founder’s vision and grit is just as important as the numbers on a spreadsheet, in IVF, the stories behind the embryos matter as much as their grades.
So, to my fellow practitioners and investors in healthcare technology, I say this: Let’s embrace AI, but let’s not forget the wisdom that comes from years of experience. Let’s not be swayed by promises of perfection. Instead, let’s focus on integrating AI in a way that enhances our human capabilities, respects the uniqueness of each case, and ultimately, serves our patients better.